Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco,.

by Leah Sherwood
January 9, 2026

Earlier lines of cilta-cel linked to better immune fitness in myeloma

Leah Sherwood January 8, 2026

Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses the ASH 2025 abstract titled, “Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study.”

Read More ➔

hand of a lab technician holding blood tube test and background a rack of color tubes with blood samples other patients / laboratory technician holding a blood tube test

Triplet therapy shows efficacy, tolerability, and transplant potential in BPDCN

Leah Sherwood January 7, 2026

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm, according to the results of a phase 2 trial presented during the 67th American Society of Hematology Annual Meeting and Exposition.

Read More ➔

What are the therapeutic combinations in large cell lymphoma?

SOHO Insider Editors January 6, 2026

In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific antibodies, and discuss ongoing phase 3 trials.

Read More ➔

Dr. Avalos highlights ASH 2025 takeaways, the future of blood cancer

Leah Sherwood January 5, 2026

Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, discusses the biggest highlights from the 67th American Society of Hematology Annual Meeting & Exposition. Dr. Avalos was president of ASH from January to December 2025.

Read More ➔

Novel protein degraders target myeloma

SOHO Insider Editors January 5, 2026

In this video interview with SOHO Insider, Pan-Yu Chen, PhD, associate director of Translational Medicine at Opna Bio, presents her ASH abstract on a novel degrader program for relapsed multiple myeloma.

Read More ➔